How do you approach treating thoracic disease in the setting of oligometastatic NSCLC in the era of immunotherapy/targeted agents?
Updated NCCN guidelines advise for definitive treatment of the thoracic disease (with option of initial systemic therapy). How do you balance these recommendations in the era of immunotherapy and targeted biologics for patients with favorable molecular results?
Community PollStarted
How do you approach treating locally advanced thoracic disease in the setting of oligometastatic NSCLC?
6 physicians have voted
Join Mednetto vote and see how they answered.